June 25-29 2023
For the full Searchable DIA program click here
Monday, June 26 • 2:45pm – 3:15pm
Component Type: Workshop
Level: Basic
Should pharmaceutical risk management be a purely compliance driven activity, or is it genuinely an area that could add value to healthcare systems? Discuss and debate with Axian Consulting!
Learning Objectives: Discuss major perspectives on risk management; Identify how pharma takes this area forward.
Chair: Marie-Claire Wilson, MD, MA
Tuesday, June 27 • 4:00pm – 5:00pm
Component Type: Session
Level: Intermediate
CE: ACPE 1.00 Knowledge UAN: 0286-0000-23-592-L04-P; CME 1.00; RN 1.00
This session will describe recent advances in a number of pharmacovigilance areas, including controlled distribution systems, safety registries, and the use of indication data in safety signal assessment.
Learning Objectives: Discuss how to prepare to use digital tools to improve controlled distribution systems; Describe how to improve patient retention in safety registries; Assess how to properly account for the role of indication in the assessment of safety signals.
Chair: Alan Hochberg
Speakers:
Design Considerations When Digitizing a Controlled Distribution System (Andrew Hobbs)
Combining a Site Network and Nested Sub Study Approach to a Safety Registry for Increased Patient Retention (Abbe Steel, MSc)
Effect or Expect? Understanding your Indicated Population to Contextualize Safety Signals (Ashley Vassilaros Howell, PhD, MPH)
Wednesday, June 28 • 10:30am – 11:30am
Component Type: Session
Level: Intermediate
CE: ACPE 1.00 Knowledge UAN: 0286-0000-23-615-L04-P; CME 1.00; RN 1.00
The outcomes of additional risk minimization measures (aRMM or REMS ETASU) could be improved through the application of learnings from behavioural and implementation science, providing MAHs with more effective, easily measurable programs.
Learning Objectives: Describe how additional risk minimization measures could benefit from the application of principles from behavioral and implementation sciences; Discuss which models/theories frameworks may be most applicable for improving the outcomes of additional risk minimization measures; Identify and explore the potential of behavioral and implementation sciences in aRMM.
Chair: Marie-Claire Wilson, MD, MA
Speakers:
Practical Applications of Behavioral Science in Drug Safety (James Duhig, PhD)
Academic Update (Elaine H Morrato, DrPH, MPH)
Update on Research into Behavioral Science and Drug Safety (Sibel D. Guerler, MSc)